肿瘤微环境
烟酰胺磷酸核糖转移酶
结直肠癌
巨噬细胞极化
癌症研究
细胞毒性T细胞
炎症
医学
肿瘤进展
癌变
下调和上调
免疫学
癌症
生物
内科学
肿瘤细胞
基因
酶
NAD+激酶
表型
生物化学
体外
作者
Sun Mi Hong,A‐Yeon Lee,Byeong‐Ju Kim,Jeong‐Eun Lee,Su‐Yeon Seon,Yu‐Jin Ha,J Ng,Gyesoon Yoon,Su Bin Lim,Michael J. Morgan,Jong‐Ho Cha,Dakeun Lee,You‐Sun Kim
标识
DOI:10.1002/advs.202303177
摘要
Abstract Nicotinamide phosphoribosyltransferase (NAMPT) is a metabolic enzyme with key roles in inflammation. Previous studies have examined the consequences of its upregulated expression in cancer cells themselves, but studies are limited with respect to its role in the other cells within the tumor microenvironment (TME) during colorectal cancer (CRC) progression. Using single‐cell RNA sequencing (scRNA‐seq) data, it is founded that NAMPT is highly expressed in SPP1 + tumor‐associated macrophages (TAMs), a unique subset of TAMs associated with immunosuppressive activity. A NAMPT high gene signature in SPP1 + TAMs correlated with worse prognostic outcomes in CRC patients. The effect of Nampt deletion in the myeloid compartment of mice during CRC development is explored. NAMPT deficiency in macrophages resulted in HIF‐1α destabilization, leading to reduction in M2‐like TAM polarization. NAMPT deficiency caused significant decreases in the efferocytosis activity of macrophages, which enhanced STING signaling and the induction of type I IFN‐response genes. Expression of these genes contributed to anti‐tumoral immunity via potentiation of cytotoxic T cell activity in the TME. Overall, these findings suggest that NAMPT‐initiated TAM‐specific genes can be useful in predicting poor CRC patient outcomes; strategies aimed at targeting NAMPT may provide a promising therapeutic approach for building an immunostimulatory TME in CRC progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI